echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Eur Urol: In ccRCC patients, how effective is PARP1 in predicting the response to PD-L1 blockade?

    Eur Urol: In ccRCC patients, how effective is PARP1 in predicting the response to PD-L1 blockade?

    • Last Update: 2021-11-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Immune checkpoint inhibitors (ICI) have become key treatments for many cancers, including clear cell renal cell carcinoma (ccRCC)
    .


    However, only some patients can benefit, and it is difficult to identify responders from non-responders


    Only some patients can benefit, and it is difficult to identify responders from non-responders.


    Currently, Immune Checkpoint Inhibitors (ICI) have become a key drug for the treatment of clear cell renal cell carcinoma (ccRCC), but their efficacy is limited and responders cannot be identified
    .

    Recently, researchers from Japan published an article in the journal Eur Urol.
    They used RNA sequencing data from 311 patients to investigate the significance of PARP1 in ccRCC.
    These patients have participated in a prospective clinical trial of PD-1 blockade..

    The significance of PARP1 in ccRCC was investigated.
    These patients participated in the prospective clinical trial of PD-1 blockade .
    The significance of PARP1 in ccRCC was investigated.
    These patients all participated in the prospective clinical trial of PD-1 blockade.

    The results of the study found that among patients treated with nivolumab (n=181), the overall survival rate (OS) of the lower PARP1 expression group was significantly higher than that of the higher PARP1 group (p=0.
    006), and the PARP1 status was significantly related to OS (risk Ratio [HR] 1.
    7; p=0.
    007)
    .


    In contrast, for patients treated with everolimus (n=130), PARP1 status had no significant effect on progression-free survival (PFS; p=0.


    In addition, in patients with PBRM1 mutant ccRCC treated with nivolumab, PARP1 status was significantly correlated with PFS (HR 2.
    6; p=0.
    007) and OS (HR 3.
    5; p=0.
    016)
    .

    Progression-free survival and overall survival of patients with advanced clear cell renal cell carcinoma treated with Nivolumab

    Progression-free survival and overall survival of patients with advanced clear cell renal cell carcinoma treated with Nivolumab

    In summary, PARP1 can be used as a biomarker to predict the response of PBRM1 mutant ccRCC patients to ICI treatment
    .


    In addition, immune checkpoint inhibitors (ICI) are key drugs for the treatment of many cancers


    PARP1 can be used as a biomarker to predict the response of PBRM1 mutant ccRCC patients to ICI treatment PARP1 can be used as a biomarker to predict the response of PBRM1 mutant ccRCC patients to ICI treatment

    Original source:

    Original source:

    Masayuki Hagiwara, Atsushi Fushimi, Kazuhiro Matsumoto et al.


     

    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.